Search
Prospective Study of Pravastatin in Elderly People at Risk (PROSPER)
Epidemiologic study ongoing in 2001 in Scotland, Ireland & the Netherlands.
Patient population:
- 5000-6000 men & women with vascular disease or risk factors for cardiovascular disease, aged 70-82 years
Study monitors:
1) cardiovascular health
2) cognitive function
3) disability
Pravastatin 40 mg/day vs placebo
Results:
1) average follow-up of 3 years
2) mean cholesterol level 147 mg/dL lowered by 38% in pravastatin group
3) combined endpoint myocardial infarction & stroke (fatal & non-fatal) significantly lower in pravastatin group (14.1% vs 16.2%)
-> myocardial infarction significantly reduced, but stroke was NOT
4) cognition & disability NOT significantly affected
5) new cancers occurred significantly more often in the pravastatin group
Related
dementia; Alzheimer's disease & related dementias (ADRD)
hyperlipidemia
pravastatin (Pravachol)
General
clinical trial
prospective cohort study; prospective study
epidemiologic study
References
- Marx J. Science 294:508, 2001
- Journal Watch 23(3):23, 2003
Shepherd J et al,
Pravstatin in elderly individuals at risk of vascular disease
(PROSPER): a randomized controlled trial.
Lancet 36:1623, 2002
PMID: 12457784
Collins R & Armitage J,
High risk elderly patients PROSPER from cholesterol-lowering
therapy.
Lancet 360:1618, 2002
PMID: 12457780
http://www.thelancet.com/journal/vol360/iss9346/full/llan.360.9346.original_research.23196.1